metformin actavis 750 mg depottabletti
actavis group ptc ehf - metformini hydrochloridum - depottabletti - 750 mg - metformiini
metformin actavis 1000 mg depottabletti
actavis group ptc ehf - metformini hydrochloridum - depottabletti - 1000 mg - metformiini
brandasit 50 mg / 1000 mg tabletti, kalvopäällysteinen
genepharm s.a. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja sitagliptiini
brandasit 50 mg / 850 mg tabletti, kalvopäällysteinen
genepharm s.a. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja sitagliptiini
forminet 1000 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - metformin hydrochloride - tabletti, kalvopäällysteinen - 1000 mg - metformiini
forminet 850 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - metformin hydrochloride - tabletti, kalvopäällysteinen - 850 mg - metformiini
forminet 500 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - metformin hydrochloride - tabletti, kalvopäällysteinen - 500 mg - metformiini
segluromet
merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.
competact
cheplapharm arzneimittel gmbh - pioglitatsoni, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.
eucreas
novartis europharm limited - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.